Productivity savings from colorectal cancer prevention and control strategies

American Journal of Preventive Medicine

Volumn 41, Issue 2, 2011, Pages

  Bradley, Cathy J ^a,b   Lansdorp Vogelaar, Iris ^c   Yabroff, K Robin ^d   Dahman, Bassam ^a   Mariotto, Angela ^d   Feuer, Eric J ^d   Brown, Martin L ^d  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FLUOROURACIL; FOLINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; CANCER THERAPY; COLORECTAL CANCER; COST CONTROL; FEMALE; HEALTH CARE COST; HORMONE SUBSTITUTION; HUMAN; MALE; OUTCOME ASSESSMENT; PRODUCTIVITY; RISK FACTOR;

COLORECTAL NEOPLASMS; COMPUTER SIMULATION; COST OF ILLNESS; COST SAVINGS; COST-BENEFIT ANALYSIS; EFFICIENCY; FEMALE; HUMANS; MALE; MASS SCREENING; MODELS, ECONOMIC; RISK FACTORS; UNITED STATES;

EID: 79960490112     PISSN: 07493797     EISSN: 18732607     Source Type: Journal    
DOI: 10.1016/j.amepre.2011.04.008     Document Type: Article

References (40)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 5 2010 277 300
2. D.K. Epsey, X.C. Wu, and J. Swan Annual report to the nation on the status of cancer, 19752004, featuring cancer in American Indians and Alaska Natives Cancer 110 10 2007 2119 2152 (Pubitemid 350100734)
3. J. Swan, N. Breen, R.J. Coates, B.K. Rimer, and N.C. Lee Progress in cancer screening practices in the U.S.: results from the 2000 National Health Interview Survey Cancer 97 6 2003 1528 1540 (Pubitemid 36297783)
4. I. Vogelaar, M. van Ballegooijen, and D. Schrag How much can current interventions reduce colorectal cancer mortality in the U.S.? Mortality projections for scenarios of risk-factor modification, screening, and treatment Cancer 107 7 2006 1624 1633 (Pubitemid 44546924)
5. C.P. Gross, M.S. Andersen, H.M. Krumholz, G.J. McAvay, D. Proctor, and M.E. Tinetti Relation between Medicare screening reimbursement and stage at diagnosis for older patients with colon cancer JAMA 296 23 2006 2815 2822 (Pubitemid 44969181)
6. J.S. Mandel, J.H. Bond, and T.R. Church Reducing mortality from colorectal cancer by screening for fecal occult blood Minnesota Colon Cancer Control Study N Engl J Med 328 19 1993 1365 1371 (Pubitemid 23131388)
7. B.K. Edwards, M.L. Brown, and P.A. Wingo Annual report to the nation on the status of cancer, 19752002, featuring population-based trends in cancer treatment J Natl Cancer Inst 97 19 2005 1407 1427 (Pubitemid 41520077)
8. A.L. Potosky, L.C. Harlan, R.S. Kaplan, K.A. Johnson, and C.F. Lynch Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer J Clin Oncol 20 5 2002 1192 1202 (Pubitemid 34177424)
9. A. Mariotto, J.L. Warren, K.B. Knopf, and E.J. Feuer The prevalence of patients with colorectal carcinoma under care in the U.S. Cancer 98 6 2003 1253 1261 (Pubitemid 37099911)
10. A.B. Mariotto, K.R. Yabroff, Y. Shao, E.J. Feuer, and M.L. Brown Projections of the cost of cancer care in the U.S.: 20102020 J Natl Cancer Inst 103 2011 1 12
11. National Cancer Institute National Cancer Institute 2006 Fact Book obf.cancer.gov/financial/attachments/06Factbk.pdf 2007
12. I. Vogelaar, M. van Ballegooijen, A.G. Zauber, J.D. Habbema, and E.J. Kuipers Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening J Natl Cancer Inst 101 20 2009 1412 1422
13. M. Pignone, S. Saha, T. Hoerger, and J. Mandelblatt Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force Ann Intern Med 137 2 2002 96 104 (Pubitemid 34779153)
14. National Cancer Institute's Cancer Intervention and Surveillance Modeling Network National Cancer Institute website cisnet.cancer.gov
15. C.J. Bradley, K.R. Yabroff, B. Dahman, E.J. Feuer, A. Mariotto, and M.L. Brown Productivity costs of cancer mortality in the U.S.: 20002020 J Natl Cancer Inst 100 24 2008 1763 1770
16. K.R. Yabroff, C.J. Bradley, A.B. Mariotto, M.L. Brown, and E.J. Feuer Estimates and projections of value of life lost from cancer deaths in the U.S. J Natl Cancer Inst 100 24 2008 1755 1762
17. B. Morson President's address The polyp-cancer sequence in the large bowel Proc R Soc Med 67 6 1974 451 457
18. T. Muto, H.J. Bussey, and B.C. Morson The evolution of cancer of the colon and rectum Cancer 36 6 1975 2251 2270
19. National Health Interview Survey CDC website www.cdc.gov/nchs/nhis.htm
20. T. André, C. Boni, and L. Mounedji-Boudiaf; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer N Engl J Med 350 23 2004 2343 2351
21. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators Efficacy of adjuvant fluorouracil and folinic acid in colon cancer Lancet 345 8955 1995 939 944
22. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer J Clin Oncol 17 5 1999 1356 1363
23. S. Gill, C.L. Loprinzi, and D.J. Sargent Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22 10 2004 1797 1806 (Pubitemid 41095169)
24. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 23 2004 2335 2342 (Pubitemid 38702844)
25. C.G. Moertel, T.R. Fleming, and J.S. Macdonald Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer J Clin Oncol 13 12 1995 2936 2943
26. C.G. Moertel, T.R. Fleming, and J.S. Macdonald Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report Ann Intern Med 122 5 1995 321 326
27. D. Cunningham, Y. Humblet, and S. Siena Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 4 2004 337 345 (Pubitemid 38944402)
28. L.B. Saltz, J.V. Cox, and C. Blanke Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer Irinotecan Study Group N Engl J Med 343 13 2000 905 914
29. L. Saltz, D. Niedzwiecki, and D. Hollis Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803 J Clin Oncol 25 23 2007 3456 3461 (Pubitemid 47310883)
30. A. de Gramont, A. Figer, and M. Seymour Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 16 2000 2938 2947 (Pubitemid 30644117)
31. R.M. Goldberg, D.J. Sargent, and R.F. Morton A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 1 2004 23 30 (Pubitemid 41095110)
32. Colorectal Cancer and Mortality Projections National Cancer Institute cisnet.cancer.gov/projections/colorectal
33. U.S. Department of Labor, Bureau of Statistics and U.S. Department of Commerce, Economics and Statistics Administration, U.S. Census Bureau Current Population Survey, Design and Methodology, Technical Paper CPS TP63, Washington DC www.bls.census.gov/cps/tp/tp63.htm
34. S. Grosse Appendix I: productivity loss tables A.C. Haddix, S.M. Teutsch, P.S. Corso, Prevention effectiveness: a guide to decision analysis and economic evaluation 2nd ed. 2003 Oxford University Press New York NY 255 257
35. Consumer Price Index U.S. Department of Labor Bureau of Statistics website stats.bls.gov/cpi/home.htm#data
36. D. Schrag The price tag on progresschemotherapy for colorectal cancer N Engl J Med 351 4 2004 317 319 (Pubitemid 38944397)
37. W. Demark-Wahnefried Cancer survival: time to get moving? Data accumulate suggesting a link between physical activity and cancer survival J Clin Oncol 24 22 2006 3517 3518 (Pubitemid 46630518)
38. A.E. Coghill, P.A. Newcomb, and P.T. Campbell Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer Gut 60 4 2011 491 498
39. A. Vrieling, and E. Kampman The role of body mass index, physical activity, and diet in colorectal cancer recurrence and survival: a review of the literature Am J Clin Nutr 92 3 2010 471 490
40. E. Cho, S.A. Smith-Warner, and J. Ritz Alcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies Ann Intern Med 140 8 2004 603 613